Biosimilars

An observational study indicates that the Oncology Care Model led to reduced use of some high-cost supportive care medications, suggesting the potential for alternative payment models to drive value-based changes in cancer medication use. Read More ›

The findings of a simulation modeling analysis demonstrate that conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb provides significant cost-savings, which could be reallocated on a budget-neutral basis to provide expanded access to additional prophylaxis or to antineoplastic therapy in patients with diffuse large B-cell lymphoma. Read More ›

A pharmacokinetic study demonstrated bioequivalence between SB12 and the eculizumab reference products, along with comparable pharmacodynamics, safety, and immunogenicity. Read More ›

The preliminary results of a phase 2 study indicate that the combination of rituximab biosimilar plus pegylated interferon α-2b was well-tolerated and yielded responses in newly diagnosed advanced indolent B-cell NHL. Read More ›

A biosimilar adoption integration process that included full staff education, physician consent, and systematic auto- conversion proved to be feasible and scalable, and resulted in rapid conversion from reference product to FDA-approved biosimilar. Read More ›

A retrospective, cross-sectional review reported significant uptake of biosimilar filgrastim products in Medicare Part D from 2015 to 2019 being associated with a small decrease in aggregate spending, essentially unchanged per-unit spending, and increased spending per beneficiary on filgrastim products, all attributed to the inability of Medicare Part D to directly negotiate prices with manufacturers. Read More ›

Prospective evaluation of real-world biosimilar-related cost-savings and adoption indicates that biosimilar utilization in community oncology practices can result in significant cost-savings. Read More ›

The preliminary findings of a retrospective study that analyzed healthcare claims from the Biologics and Biosimilars Collective Intelligence Consortium’s Distributed Research Network between 2016 and 2020 indicate that utilization of biosimilar trastuzumab-anns increased over time, whereas the use of trastuzumab reference decreased. Read More ›

Simulation models demonstrate substantial cost-savings realized by conversion to biosimilar pegfilgrastim-cbqv for chemotherapy-induced (febrile) neutropenia prophylaxis in patients with metastatic pancreatic cancer, and that these cost-savings could be reallocated to provide access to antineoplastic treatment on a budget-neutral basis. Read More ›

This past year, the COVID-19 pandemic continued to impact the practice of medicine and the dissemination of treatment advances presented in scientific forums. Read More ›

Page 2 of 7


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: